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Abstract: There is a high medical need to improve the effectiveness of the treatment of pain 
and traumatic soft tissue injuries. In this context, electrostimulating devices have been used 
with only sporadic success. There is also much evidence of endogenous electrical signals that 
play key roles in regulating the development and regeneration of many tissues. Transepithelial 
potential gradients are one source of the direct current (DC) electrical signals that stimulate and 
guide the migration of inflammatory cells, epithelial cells, fibroblasts and mesenchymal stem 
cells to achieve effective wound healing. Up to now, this electrophysiological knowledge has 
not been adequately translated into a clinical treatment. Here, we present a mobile, handheld 
electroceutical smart device based on a microcontroller, an analog front end and a battery, which 
generates DC electric fields (EFs), mimicking and modulating the patient’s own physiological 
electrical signals. The electrical stimulation is applied to percutaneous metal probes, which are 
located close to the inflamed or injured tissue of the patient. The treatment can be used in an 
ambulatory or stationary environment. It shows unexpectedly, highly effective treatment for 
certain severe neurological pain conditions, as well as traumatic soft tissue injuries (muscle/
ligament ruptures, joint sprains). Without EF intervention, these conditions, respectively, are 
either virtually incurable or take several months to heal. We present three cases – severe chronic 
cluster headache, acute massive muscle rupture of the rectus femoris and an acute ankle sprain 
with a ruptured anterior talofibular ligament – to demonstrate clinical effectiveness and discuss 
the fundamental differences between mimicking DC simulation and conventional transcutaneous 
electric nerve stimulation (TENS) or TENS-like implanted devices as used for peripheral nerve 
cord, spinal cord or dorsal root stimulation.
Keywords: electroceutical device, tissue regeneration, pain, direct current stimulation, electric 
field
Introduction
A range of electrostimulating devices is used for pain treatment. For transcutaneous 
electric nerve stimulation (TENS), percutaneous stimulation (e.g., electroacupunc-
ture) or surgically implantable devices such as peripheral nerve stimulators (PNS), 
spinal cord stimulators (SCS) or dorsal root ganglion (DRG) stimulators, the method 
is basically the same. Dynamic, pulsed bipolar electric stimuli (1–70 V, 1–90 mA, 
1–1200 Hz, pulse width of 0.2–250 ms) are applied to override the electrical capacity 
of nerves to generate further action potentials, thus interrupting the afferent pathways 
in locomotive or neurological pain conditions. These electrical devices are widely 
established clinically, although their clinical efficacy is not unequivocally proven, 
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and the treatment only aims at suppressing pain.1–3 There 
is no clinical claim or evidence that TENS or TENS-like 
treatments improve regeneration or healing. Another class 
of electrostimulating devices aims at thermal or nonthermal 
electrochemical ablation (percutaneous thermocoagulation 
or electrolysis) to reduce anatomical pressure from a nerve, 
to ablate nociception or to promote consecutive angiogenesis 
and tissue repair.4,5
However, electrophysiological phenomena are not 
restricted to dynamic action potentials. Both in the extracel-
lular matrix and within cells, ions and proteins/peptides are 
charged, and ion channels and ion transporters in the cell 
membrane regulate the flow of these charged molecules. 
Each tissue produces ionic currents and consequently electric 
fields (EFs) with a defined orientation and intensity. These 
EFs interact with charged ions and peptides by electrostatic 
forces, electrophoresis and electro-osmosis.6 For example, 
muscle-tissue inflammation as observed in painful trigger 
points is associated with a locally increased concentration of 
proinflammatory cytokines and H+ ions, resulting in acidosis 
and local changes in electrical properties that favor increased 
electrical conductivity of the inflamed tissue.7
Another example is the transepithelial potential (TEP) 
difference. In epithelial tissues, epithelial cells frequently 
generate a net influx of Na+ ions toward the parenchyma. 
Thus, epithelial cells, which are linked to each other by 
tight junctions that maintain ionic differences between the 
inner and outer aspects of the epithelium, create multiple, 
parallel and interlinked microbatteries that generate the TEP 
difference.8 Epithelial wounds cause a local collapse of the 
electrical resistance and a short-circuiting of the TEP locally 
because of the destruction of the tight junction seals and the 
build-up of edema. Depending on the size and location of 
the wound, the species and the specific tissue injured, this 
would induce small local direct currents (DCs); in human 
beings, these electrical signals are of the order of 140 mV/
mm and the drive current is ~20–50 µA/cm.2,8 A large body 
of evidence proves that these small wound-generated DC 
EFs are predominant directional cues for wound healing 
and tissue regeneration.9–11 DC EFs guide and stimulate the 
migration of inflammatory cells, epithelial cells and fibro-
blasts.12,13 Depending on the orientation and intensity of the 
EFs, fibroblasts migrate toward or away from the wound, 
leading to an opening or closing of the wound.13 Small DC 
EFs also stimulate and direct the growth of spinal neurons 
(Borgens), astrocytes (Baer), mesenchymal stem cells (Zhao), 
monocytes and macrophages (Hoare), thus steering the 
process of regeneration of different tissues in mammals.14–17
This recently gained electrophysiological knowledge has 
inspired new clinical applications to improve regeneration. 
Tissue engineering is making huge strides, and new electri-
cal devices are being tested to improve wound healing.18 
However, we believe the clinical impact could and should 
be much wider.
In this article, we present a patented electroceutical treat-
ment device that for the first time translates the knowledge of 
small steady DC EFs into the clinical treatment of neurologic 
and locomotive disorders. In contrast to the electrical stimula-
tor devices described earlier, this electrical stimulator deliv-
ers a unipolar, steady DC over 30 minutes duration, which 
mimics and increases physiological EFs to modulate local 
tissue inflammation and to trigger the regeneration of nerves, 
muscles, ligaments and tendons. Selected case histories are 
presented to exemplify the treatment procedure.
Materials and methods
In developing the device we faced four challenges. First, 
between electrical probes inserted into the subcutaneous 
tissue or placed on the skin, a time- and voltage-dependent 
electrical resistance is observed, resulting in an unstable 
current over the time of stimulation. Second, the active 
stimulation electrode most commonly should be the cathode, 
inducing the desired buffering of acidosis and creating an 
EF to attract cells by galvanotaxis, whereas the indifferent 
electrode should be the anode. Third, for the anode, we had 
to find a solution for the oxidative electrolysis that induces 
acidosis and oxidative interaction with the stainless steel 
alloy, transporting metal ions into the tissue. Finally, senso-
rimotor irritation could be observed when switching a DC 
current on and off in the human body.
It was decided to develop a mobile handheld smart device, 
based on a microcontroller, an analog front end and a bat-
tery (Figure 1). The device generates a constant DC with 
predefined and selectable values up to 540 µA for a treatment 
time of 30 minutes. The current is delivered to the patient 
by an anodal skin pad electrode and a cathodal subcutane-
ous/intramuscular set of one to nine stainless steel needle 
electrodes. The current output is selected depending on the 
needle diameter, tissue, body region and type of disease.
To avoid sensory effects at the start and end of the 
treatment, a ramping in/out of the selected current was pro-
grammed. To counteract possible habituation, the amplitude 
of the DC current was modulated by a small (±10%) and slow 
(0.1 Hz) alternating current (AC).
The given requirements are mapped by a voltage signal 
u(t) depicted in Equation 1. The described medical device is 
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manufactured by an original equipment manufacturer. It has 
been proofed and certified by a notified body of the European 
Commission (CE 0482).
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A discrete, quantif ied signal generator algorithm was 
implemented to create the desired digital waveform pat-
terns, which could then be transformed into continuous 
analog waveforms by an analog front end. Following the 
Nyquist–Shannon sampling theorem, the signal generator 
needs to have a sample rate of at least 0.2 Hz for an undula-
tion frequency of 0.1 Hz. Analog to digital converters with a 
resolution of 12 bits are sufficient. With a voltage range of 
Figure 1 Block diagram of the medical smart device.
Notes: An analog front end is connected via a digital bus to the microcontroller. The microcontroller adjusts the analog amplifiers to generate the needed current. In order 
to keep the current at the preselected level, the output voltages Vout– and Vout+ are continuously measured and adjusted to the changing impedance of the patient. Additionally, 
the voltage difference between both outputs is measured with a high-precision measurement amplifier network to compensate for surrounding noise (e.g., induced by 
power-line frequency).
Abbreviations: LCD, liquid-crystal display; ADC, analog to digital converter; DC, direct current; I2C, inter-integrated circuit; I/O, digital input/output; SPI, serial peripheral 
interface; PAD, electrically conductive self-adhesive pad; DAC, digital to analog converter; RMS, root mean square; GND, ground; RISC, reduced instruction set computer.
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0–35 V, the measurement resolution is limited to 8.54 mV. 
With a minimal impedance of 3 kW, the minimum current 
measuring resolution is 2.84 µA.
For safety reasons, the overall current is continuously 
checked and limited to a maximum of 540 µA; in hazardous 
situations, the complete signal amplification and output of 
the device are turned off.
The cathodal output is connected to one to nine stainless 
steel probes via a passive equalizer. The impedance of each 
inserted needle may vary depending on the applied voltage, 
needle diameter, location and depth of insertion. Different 
sets of pre-resistors (5–50 kW) are used to keep the differ-
ence in the output current between needle probes to <10%.
A stand-alone real-time clock controls the stimulation 
time. The flash memory stores the log file of treatment-relevant 
data, such as number of treatments, treatment time and date, 
electrical parameters and errors, if any. The readout of data 
can be done comfortably on a PC via Universal Serial Bus.
The user menu is displayed on the liquid-crystal display 
(LCD). The user is walked through the menu with all informa-
tion and tests mandatory for medical devices and the selection 
of the predefined DC stimulation levels. Status information 
such as remaining treatment time and battery charge condi-
tion is also displayed. Errors or hazardous situations are 
displayed on the LCD and signaled by an alarm tone.
Inflamed or damaged tissue shows pain and is sensitive 
to pressure (locus dolendi point). In clinical use, the patient 
indicates the most painful area, which is confirmed by applying 
pressure (case 1) and if meaningful, in recourse to a magnetic 
resonance imaging (MRI) examination (cases 2 and 3). Then, 
the needle is carefully inserted until the patient feels a sharp 
increase in pain, indicating that the tip of the needle has reached 
the pathological tissue. Second, the needle is redrawn for a few 
millimeters, just as to avoid further eliciting pain. Depending 
on the size of the area to be treated, up to nine needle probes 
are inserted, usually 1 probe/cm2. Hereby, the depth of insertion 
is defined by the location of the area to be treated and ranges 
from 0.5 cm (e.g., temporal region, case 1) to 6 cm (case 2). 
The conductive skin pad is placed at least 20 cm away from the 
needle electrodes. The anodal output is then connected to the 
skin pad, and the cathodal output to the needle probes via the 
equalizer. The physician then selects the stimulation level from 
the menu and starts the stimulation for the next 30 minutes.
Results
Patient cases
The following cases refer to single patients, who chose to be 
treated with the percutaneous DC stimulation on the basis 
of “compassionate use”. These cases do not constitute a 
clinical study and therefore do not have to be reviewed and 
approved by an institutional review board (ethics committee). 
Written informed consent has been obtained by all patients 
to have the case details and accompanying images published. 
Importantly, the individual cases presented are not selected 
super responders; however, they are wholly representative of 
many other cases we have treated, as we indicate in each of 
the following three sections.
Cluster headache (CH)
CH is considered to be the most severe human pain condi-
tion, with a prevalence similar to that of multiple sclerosis. 
Sufferers experience severe, stabbing, one-sided pain in the 
vicinity of the eye, with a frequency ranging from one to12 
attacks per day. CH occurs in an episodic form (prevalence 
0.1%), with attacks mostly during spring and autumn, pain-
free intervals in between and a chronic form (prevalence 
0.01%) in which attacks occur for >11 months/year. Attacks 
last between 15 and 90 minutes, and in most cases can only 
be treated with oxygen inhalation and triptan nasal sprays or 
injections. Verapamil, topiramate and lithium are commonly 
used as prophylactic treatments. Available pharmacological 
treatments are hampered by unwanted side effects, and there 
is an urgent need for new non-pharmacological treatment 
alternatives. The annual treatment costs vary between 5,000 
and 20,000 euros/patient, resulting in a socioeconomic impact 
of 1–4 billion euros/year (USA).19–21
A 52-year-old male patient had suffered from episodic 
CH for 12 years that had turned into a chronic form 1 year 
before treatment. Daily attacks were treated with oxygen 
inhalation and a triptan injection. Prophylactic treatment 
with verapamil had to be stopped 2 years previously after 
he developed swelling of his legs and bradycardia. Under 
the aforementioned treatment, his headache diary showed 
five to eight attacks a day, each lasting 10–30 minutes, with 
a pain intensity score of 4–10 on a scale from 0 = no pain 
at all to 10 = unbearable pain. The patient had consulted 12 
neurological specialists. He was depressed, sociophobic and 
suicidal. The desperate patient decided to try a DC stimula-
tion treatment on a compassionate-use basis. He initially 
received four DC stimulations, one per week, followed by 
two more DC stimulations at weeks 8 and 12 after the first 
treatment. DC stimulations lasted 30 minutes each. The anode 
of the stimulating device was attached to a surface electrode 
(adhesive pad) on the upper arm. The cathode was attached to 
a maximum of seven needles 0.3 × 30 mm. Two needles were 
placed below the eye beneath the maxilla, and two needles 
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were inserted at the temporal region above the temporal 
branch of the facial nerve and the deep temporal nerve. One 
needle was placed each at the lateral part of the nose, the lat-
eral end of the eyebrow and at the occipital region above the 
greater occipital nerve. Depth of insertion varied between 4 
and 15 mm, depending on the treated area. A DC of 210 µA, 
undulating ±10% with a frequency of 0.1 Hz, was applied 
for 30 minutes. After the first treatment, the continuous pain 
disappeared and the frequency and pain intensity of attacks 
were reduced by >50%. The condition improved continuously 
after each treatment. After the fifth treatment, the frequency 
of attacks was reduced from five to eight per day to two to 
four per week, with a pain level of 1–3 and a duration of 
<5 minutes per attack. After the sixth treatment, the attacks 
had stopped completely (Figure 2). At present, >3 years later, 
the patient is still in full remission, completely free of CHs 
(all data were taken from the patient’s daily headache diary 
recording attack frequency, pain level and duration of attacks 
as well as the use of acute medication). In a prospective case 
series analysis of chronic CH patients (n=18) being treated in a 
similar way, we observed a reduction of at least 50% in attack 
frequency, pain intensity, duration of attack and triptan intake 
in 13 patients 2 weeks after the last percutaneous DC treat-
ment, which lasted for at least 24 weeks (follow-up period).
Acute muscle rupture
Acute muscle injuries are a major problem for professional 
and amateur football, soccer and ice hockey players and 
represent 20–37% of all time-loss injuries at the men’s 
professional level (18–23% at the men’s amateur level). 
Available treatment is without proven efficacy and consists 
of various injections (Actovegin, Traumeel, autologous blood 
and platelet-rich plasma), physical therapy and extensive 
rehabilitation to reduce expensive downtime.22
A 19-year-old professional soccer player had suffered 
from an acute muscle rupture of the right rectus femoris dur-
ing a soccer game. An MRI done the following day showed 
a 5–6 cm traumatic lesion of the proximal rectus femoris, 
accompanied by a massive hemorrhage. The physicians in 
charge told the patient that he would not be able to play for 
at least 3 months and referred him to an orthopedist special-
izing in sports medicine. On the same day, he received the 
first DC stimulation treatment, followed by four more treat-
ments delivered every second day, each lasting 30 minutes. 
At each treatment, seven stainless steel needle electrodes, 
0.3 × 30 mm, were inserted around and into the muscle lesion 
to a depth of 10–50 mm and connected to the cathode. The 
anodal skin electrode was positioned at the homolateral waist. 
A total DC current of 210–540 µA (±10%, 0.1 Hz), varying 
between treatments, was delivered. Other than that the patient 
received physiotherapy for his lumbar spine only. After the 
first treatment, the patient felt a noticeable improvement. This 
was followed by a pain reduction of 80% after the second 
treatment and 100% after the third treatment. After only 
10 days, the patient was completely pain free and urged the 
treating physician to allow him to return to soccer training. 
However, because the improvement was so unexpectedly 
fast, a further MRI was scheduled on the eleventh day after 
Figure 2 Chronic CH patient with complete remission to date.
Notes: A male aged 52 years had episodic CH for 13 years, which was chronic for the past year. The average number of attacks was six per day. The average pain intensity was 
eight out of 10. He had acute therapy with oxygen, triptan and NSAIDs. The medication use had severe side effects, e.g., tremor, depression, sleep disturbance, inability to work 
and suicidality. The number of physicians consulted was 10. The number of percutaneous DC treatments was five. Symptoms improved after the first treatment and disappeared 
within 6 weeks after the last treatment. The patient’s CH remains in complete remission to this day – follow-up >3 years. Red bars indicate severity of headache calculated as 
the product of number, duration and pain intensity of the daily attacks. Blue bars indicate the DC treatments. x-axis represents the number of days after the first treatment.
Abbreviations: CH, cluster headache; NSAID, nonsteroidal anti-inflammatory drugs; DC, direct current.
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the trauma, which in fact confirmed the regeneration of the 
muscle (Figure 3). A full return to sports was possible after 
3 weeks instead of the expected 3 months. Up to the date of 
this article, we have treated eight additional cases of acute 
and chronic muscle fiber rupture with electrical stimulation, 
all of which showed a comparable clinical recovery.
Ankle sprain with rupture of the anterior 
talofibular ligament
The ankle is the most commonly injured area of the body. 
Approximately 25% of all injuries of the musculoskeletal 
system involve inversion injuries of the ankle, and ~50% of 
these injuries are sports related (soccer, basketball, running, 
dancing). The anterior talofibular ligament is damaged in two-
thirds of all injuries, ranging from simple sprain to complete 
rupture. Treatment is based upon the stages of biological 
ligament healing – the proliferation phase from 6 weeks to 
3 months after the trauma, and the remodeling phase up to 
1 year after trauma – and consists of rest, ice, immobilization, 
support and functional treatment.23
A 25-year-old female suffered from a severe traumatic 
injury of the right ankle during a soccer game. The ankle 
was swollen and painful. The MRI showed a rupture of the 
anterior talofibular ligament. On days 1, 4 and 10 following 
the trauma, the patient received 30 minutes of DC EF stimula-
tion. Six stainless steel needle electrodes, 0.3 × 30 mm, were 
inserted at the lateral aspect of the ankle, close to and directly 
into the most painful area, which corresponded to the lesion 
of the ligament. The depth of insertion was 5–10 mm, depend-
ing on the location of the needle. All needles were connected 
to the cathode. The anodal skin electrode was positioned at 
the homolateral thigh. A total DC current of 270 µA (±10%, 
0.1 Hz) was delivered. The day after the first treatment (day 
2 post-trauma), pain and swelling were significantly reduced 
and the patient began walking without crutches. On day 4, 
before the second treatment, walking was almost normal. On 
the day of the third treatment (day 10 after trauma), she was 
asked to start soccer training again. To verify the unexpected 
clinical progress, a second MRI was undertaken on day 14 
after trauma, which showed a significant regeneration of the 
ruptured ligament. A third MRI, 6 weeks after the injury, 
showed an almost normal ligament, without the expected 
typical signs of secondary scar tissue (Figure 4). A total of 
10 other patients with ankle sprain demonstrated a likewise 
clinical uncommon reduction in swelling and pain within up 
to three treatments.
We include two videos (Videos S1 and S2) as supple-
mentary materials (link: https://www.boewing-molsberger.
de/publications_supplementary_info/).
The first shows a patient who had suffered from severe 
CH for 6 years and after three percutaneous DC stimula-
tions, reports a marked improvement. The video also shows 
the treatment procedure and a follow-up over 10 weeks. 
The second shows a patient with repeated muscle ruptures 
and pain, which severely limited him from playing profes-
sional ice hockey. After four percutaneous DC stimulation 
Figure 3 Acute muscle rupture of the rectus femoris.
Notes: A 19-year-old professional soccer player suffered from acute muscle rupture of the thigh during the second half of the game. He was taken out of sports for an 
expected 3 months minimum. Five percutaneous DC treatments were carried out over a 2-week period. He had noticeable improvement after the second treatment, was 
pain free after the fifth treatment and resumed sport after 3 weeks. Left: MRI on the day of the injury – hematoma with ruptured muscle fibers. Right: MRI after five DC 
treatments – 11 days after trauma. 
Abbreviations: MRI, magnetic resonance imaging; DC, direct current.
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 treatments, he has been able to play 20 games without pain 
or limitation. We deliberately chose different patients from 
the ones detailed in the paper to show that these treatments 
are effective for most of our patients.
Discussion
The preceding cases – a severe chronic nerve problem, an 
acute traumatic muscle injury and an acute joint sprain with 
an injured ligament – are different in nature, involving dif-
ferent tissues and conditions that heal over hugely variable 
time periods. However, after DC EF stimulation, they all 
followed a similar pattern of improvement. First, a signifi-
cant reduction in inflammatory signs such as pain, swelling 
and redness was observed within 1–3 hours after treatment. 
This first effect lasted up to several days. Second, after two 
to six treatments, the anti-inflammatory effect stabilized 
and further improvement up to a complete remission or 
recovery followed. These diverse conditions normally are 
difficult to treat and resolve only slowly, if at all. Using the 
same electrical stimulation technique, however, induced 1) 
strong early pain reduction; 2) anti-inflammatory effects 
and 3) long-term improvements that were strikingly more 
effective than current clinical treatments. Here, we present 
two hypotheses to explain these unusual and compelling 
clinical observations.
Fast pain reduction and anti-inflammatory 
effect
It is known that local acidosis and an increased concentra-
tion of proinflammatory cytokines is associated with local 
pain, inflammation and swelling. For example, Shah et al7 
measured the local acidotic state and various proinflamma-
tory cytokines such as CGRP, bradykinin, SP, TNF-alpha and 
IL-1beta in active muscle trigger points. It is known further 
that a DC current induces an ionic current in biological tissue, 
with cations moving toward the cathode (negatively charged 
electrode) and anions moving toward the anode (positively 
charged electrode). The DC treatment device delivers the 
current at the cathodal site via metal probes inserted directly 
into the inflamed tissue. A transdermal connective skin pad 
is used at the anode site. At the cathode, electrolysis occurs 
according to the formula 2H
2
O + 2e- → H
2
 + 2OH-. The 
liberated OH– ions lead to a locally more basic pH value. 
This shift in the pH value from acidosis to alkalosis spreads 
into the surrounding tissue by diffusion during the 30-minute 
treatment time, thus buffering the acidotic state and reduc-
ing pain and inflammation. Although this mechanism has 
not been observed directly in the ruptured muscle, it is a 
regular observation in tissue culture where local pH changes 
arise after long periods around the electrodes and have been 
observed directly in ex vivo brain slice preparations where 
Figure 4 Ankle sprain with rupture of the anterior talofibular ligament.
Notes: A 25-year-old female soccer player suffered from a severe traumatic injury of the ankle during a soccer game. The ankle was severely swollen and painful. The MRI 
showed a rupture of the anterior talofibular ligament. Percutaneous DC treatments were applied on days 1, 4 and 10 after trauma. Immediately after the first treatment, 
pain and swelling were significantly reduced and she started to walk without crutches. On day 4, before the second treatment, walking was almost normal. On the day of the 
third treatment (day 10 after trauma), she was asked to start soccer training again. To verify the unexpected clinical progress, a second MRI was undertaken on day 14 after 
trauma, showing significant regeneration of the ruptured ligament. The third MRI, 6 weeks after trauma, showed an almost completely new ligament, without the expected 
typical signs of secondary scar tissue. The arrows indicate the anatomical structure of the  anterior talofibular ligament.
Abbreviation: MRI, magnetic resonance imaging.
Day 2 after trauma Day 14 after trauma 6 weeks after trauma
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a pulsed EF was used to overcome the pH and acidosis 
changes.24 Furthermore, the electrically charged proinflam-
matory cytokines will react to the induced EF through elec-
trostatic forces and electrophoresis, perhaps concentrating 
some and reducing the concentration of others in specific 
locations. Although requiring direct laboratory testing in the 
live muscle, we suggest that the buffering of local acidosis 
and the influence on cytokines are likely to explain the fast 
decongestant and pain-reducing effect.
Long-term improvement
Static electric DC fields guide and stimulate the process of 
inflammation and regeneration of wounded tissue. The wound 
relative to the intact tissue always represents the cathodal side 
of the current. Non-mammalian vertebrates like the urodele 
or the axolotl that can regenerate complete amputated limbs 
and full organs (heart, brain, eye lens) exhibit high EFs up 
to 400 mV/mm at the injured site.10 Mammalian vertebrates 
have lost this full regenerative capacity and only exhibit 
wound-induced DC currents from 10–30 µA/cm2 (human 
fingertips) to 300 µA/cm2 (guinea pigs) and an EF of up to 
140 mV/mm.8 Thus, it can be argued that the intensity of 
the current and the strength of the resulting EF are crucial 
for the speed and the completeness of the regeneration. It 
is thought that an increased current alone, over only a short 
time span, will suffice to trigger long-lasting regenerative 
processes.25 The DC stimulation therapy described earlier 
delivers a cathodal electric current of 30–540 µA/needle to 
the injured site. This results in a 10–20-fold reinforcement 
of the naturally occurring wound DC, one to two times a 
week, for 30 minutes each time. It is hypothesized that the 
unexpectedly fast and high-quality regeneration of muscles 
and ligaments observed is in fact triggered by the therapeuti-
cally increased DC at the injured tissue.
In closing, it is important to comment on the remarkable 
ability of a single intervention, a DC EF to cure a series of 
pathologies with a widely varying etiology. The body gener-
ates its own DC electrical signals, and there is unequivocal 
evidence that they play several roles in orchestrating the 
complexity and variability of the different types of cellu-
lar responses that collectively are required for successful 
wound healing.6,8,13 DC electrical stimulation regulates cell 
proliferation, migration and differentiation of many cell 
types in cell-specific ways. This includes nerve, muscle, 
epithelial and endothelial cells; macrophages; fibroblasts; 
and mesenchymal stem cells, among many others. Not 
only do these cell types behave in cell-specific ways when 
stimulated, they also release multiple cell-specific growth 
factors and neurotransmitters and regulate the expression of 
growth factor, cytokine and neurotransmitter receptors. For 
example, DC stimulation around blood vessels stimulates 
new vessel sprouting, directed endothelial cell migration and 
the release of vascular endothelial growth factor (VEGF)6,8 
effects, which may underpin the improvements seen in CH. 
Because of this repertoire of cell-specific responses to a DC 
EF, we should expect different wounds/pathologies to react 
to DC stimulation by selecting the appropriate combination 
of cellular behaviors and responses that will enhance this 
specific healing situation.
There is nothing “magical” about a unitary intervention 
improving multiple different pathologies. By contrast, it 
reflects and emphasizes the relative ubiquity of wound-
induced electrical signals, their multiple and specific cellular 
and molecular targets and consequently, the multiplicity of 
ways in which they may be beneficial clinically.
Conclusion
TEPs generate small EFs that orchestrate cell differentiation, 
division and migration in many wound-healing and tissue-
regenerating processes. Here, we presented a new kind of 
bioelectric stimulation device delivering small direct cur-
rents and consequent EFs mimicking the TEP-induced EFs. 
Three cases of different etiology illustrate the potentially 
powerful clinical impact of this promising electroceutical 
treatment approach: CH, a very severe and costly pain con-
dition; muscle rupture, a frequent sports problem for which 
treatment of proven effectiveness is still lacking; and ankle 
sprain, the most frequent trauma injury for humans. Each 
condition showed a more rapid and lasting improvement that 
is not observed with conventional treatments. As indicated, 
we have many more cases showing the same pattern of pain 
reduction and lasting regeneration in soft-tissue conditions 
that would have otherwise healed incompletely and/or more 
slowly. We are convinced therefore that this bioelectric DC 
stimulation regime represents a transformative new approach 
for the regenerative treatment of soft-tissue conditions. Ran-
domized controlled trials are scheduled for the near future, 
as well as laboratory work aimed at reverse engineering on 
a cellular level of the clinically observed regenerative effect.
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